Diabetes

In a subanalysis of the DAPA-HF study, dapagliflozin improved CV outcomes in HFrEF patients when compared to placebo, irrespective of baseline SBP.

This 2020 expert consensus decision pathway (ECDP) provides practical guidance on the use of SGLT2i and GLP-1RAs for reducing the risk of CVD in patients with T2DM.

The Journal of the American College of Cardiology has published an expert consensus decision pathway (ECDP) on novel therapies for CV risk reduction in patients with T2DM...

This substudy of the PARAGON-HF trial demonstrated that in HFpEF patients, sacubitril/valsartan reduced the risk of a composite of renal outcomes and attenuated decline in kidney function compared to valsartan alone.

ESC 2020 Using data of the UK Biobank, this study showed that BMI and a polygenic score for diabetes have independent and additive effect on lifetime risk of diabetes, and should be used in combination for risk prediction.

Presented at the ESC congress 2020...

ESC 2020 Ertugliflozin reduced time to first HF hospitalization, total HF hospitalizations and total HF hospitalizations/CV death events in T2DM patients with ASCVD.

ESC 2020 The DAPA-CKD trial showed that dapagliflozin significantly reduced the risk of kidney failure, CV death or HF hospitalization, and all-cause mortality in patients with CKD, with and without T2DM, compared to placebo.

Presented at the ESC congress 2020 by: Prof. Hiddo Heerspink, PhD , Groningen, The Netherlands

Introduc...

This comparative cohort study used data from clinical practice from 13 countries. Results showed that initiation of SGLT2i vs. DPP-4i in adults with T2DM was associated with lower risks of HF, death, MI and stroke.

Treatment with the PCSK9 inhibitor evolocumab reduced a composite of CV events compared to placebo in ASCVD patients with and without metabolic syndrome in a similar degree.

Results from the EMPEROR-Reduced trial showed that the SGLT2 inhibitor empagliflozin significantly reduced the risk of CV death or hospitalization for heart failure in HFrEF patients with or without diabetes.

The SGLT2 inhibitor empagliflozin met the primary outcome measure in reducing risk of CV death or hospitalization for heart failure in HFrEF patients with or without diabetes, as de...

T2DM patients who developed HF alone or in combination with stroke, CKD or PAD had the highest 5-year risk of death and the greatest decrease in lifespan when compared with development of other CV and renal diseases.

Treatment with the GLP-1RA dulaglutide for a median of 5.4 years resulted in a reduction of cognitive impairment compared to placebo in T2DM patients ≥50 years, in an exploratory analysis of REWIND.

ADA 2020 The ATP citrate lyase inhibitor bempedoic acid lowered LDL-c compared to placebo in high-risk CV patients across all glycemic status subgroups, shown by a pooled analysis from four phase 3 trials.

A pooled analysis from four phase 3 trial with bempedoic acid, presented at ADA’s 80th Scientific Sessions by Lawrence Leiter (University of Toronto, ON, Canada) demonstrated ...

ADA 2020 A prespecified analysis from REDUCE-IT demonstrated that first and total (first plus recurrent) CV events were reduced with icosapent ethyl compared to placebo in patients with diabetes.

Icosapent ethyl 4 g/day resulted in substantial CV benefits in diabetes patients on background therapy of statin. Both first and total (first and recurrent) CV events were red...

ADA 2020 The SGLT2 inhibitor dapagliflozin reduced risk of new-onset T2DM in HFrEF patients, demonstrated by a prespecified analysis of the DAPA-HF trial.

A prespecified analysis of the DAPA-HF study presented at the American Diabetes Association’s (ADA’s) 80th Virtual Scientific Sessions showed that the SGLT2 inhibitor dapaglif...

Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.

In a special article collection of Diabetes Care, The Diabetes and Cardiovascular Disease EAS Study group has published the perspective ‘Issues of cardiovascular risk management in ...

Administration of 4 g/day icosapent ethyl reduced first coronary revascularizations by 34% compared to placebo in patients with elevated triglyceride levels, who had CVD or diabetes with additional CV risk factors.

First and total (first and subsequent) coronary revascularization, including coronary stenting and cardiac bypass surgery, were significantly reduced by 34% and 36%, respective...